- Home
- ZVRA
as 08-29-2025 3:35pm EST
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | CELEBRATION |
| Market Cap: | 627.7M | IPO Year: | 2015 |
| Target Price: | $22.67 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.19 - $13.16 | Next Earning Date: | 08-12-2025 |
| Revenue: | $62,020,000 | Revenue Growth: | 161.81% |
| Revenue Growth (this year): | 329.57% | Revenue Growth (next year): | 55.29% |
Stock Insider Trading Activity of Zevra Therapeutics Inc. (ZVRA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bode John B | ZVRA | N/A | Aug 19 '25 | Buy | $9.17 | 5,000 | $45,825.00 | 45,000 |
Latest Zevra Therapeutics Inc. News
ZVRA Breaking Stock News: Dive into ZVRA Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 months ago
Zevra Announces Final Results of 2025 Annual Meeting of Stockholders
Insider Monkey
3 months ago
Citizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PT
GlobeNewswire
3 months ago
All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company’s Director Nominees
Simply Wall St.
3 months ago
With 49% stake, Zevra Therapeutics, Inc. (NASDAQ:ZVRA) seems to have captured institutional investors' interest
Thomson Reuters StreetEvents
4 months ago
Q1 2025 Zevra Therapeutics Inc Earnings Call
GuruFocus.com
4 months ago
Zevra Therapeutics Inc (ZVRA) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges
Zacks
4 months ago
Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates
MT Newswires
4 months ago
Zevra Therapeutics Q1 Net Loss Narrows, Revenue Rises; Shares Gain After Hours
Compare ZVRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZVRA Zevra Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.